2-bromo-N-tert-butyl-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide → HCID 71280404, Verbindung

HRID 246754

Reaktionsgleichung

Reaktionsgleichung von HRID 246754
Br[C:2]1[N:7]=[C:6]2[C:8]([C:30]([NH:32][C:33]([CH3:36])([CH3:35])[CH3:34])=[O:31])=[CH:9][N:10]([C:11]([C:24]3[CH:29]=[CH:28][CH:27]=[CH:26][CH:25]=3)([C:18]3[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=3)[C:12]3[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=3)[C:5]2=[N:4][CH:3]=1.[F:37][C:38]1[CH:46]=[C:45]2[C:41]([C:42]([Sn](CCCC)(CCCC)CCCC)=[N:43][NH:44]2)=[CH:40][CH:39]=1>CN(C=O)C.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.[Cu]I>[C:33]([NH:32][C:30]([C:8]1[C:6]2=[N:7][C:2]([C:42]3[C:41]4[C:45](=[CH:46][C:38]([F:37])=[CH:39][CH:40]=4)[NH:44][N:43]=3)=[CH:3][N:4]=[C:5]2[N:10]([C:11]([C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=2)([C:24]2[CH:29]=[CH:28][CH:27]=[CH:26][CH:25]=2)[C:12]2[CH:13]=[CH:14][CH:15]=[CH:16][CH:17]=2)[CH:9]=1)=[O:31])([CH3:35])([CH3:34])[CH3:36]

Komponenten

6

Edukt 2

HCID 866780082-bromo-N-tert-butyl-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamideHCID 1784482326-fluoro-3-(tributylstannyl)-1H-indazole

Produkt 1

HCID 71280404HCID 71280404, VerbindungAusbeute 27 %

Reagenzien, Katalysatoren, Lösungsmittel 3

HCID 24350Copper(1+) iodide; Copper(I) iodide; Cuprous iodide; Cuprous iodide (CuI)KatalysatorHCID 178418397HCID 178418397, VerbindungKatalysatorHCID 6228DimethylformamideLösungsmittel

Reaktionsbedingungen

Temperatur
85 °C

Versuchsvorschrift

In a round-bottomed flask, 2-bromo-N-tert-butyl-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide (600 mg, 1.12 mmol) and 6-fluoro-3-(tributylstannyl)-1H-indazole (475 mg, 1.12 mmol) were dissolved in DMF (10 mL) under nitrogen. Pd(PPh3)4 (65 mg, 0.056 mmol) and CuI (43 mg, 0.224 mmol) were added and the mixture sonicated for 5 min while bubbling nitrogen. The reaction mixture was stirred at 85° C. for 16 hours. After solvent removal, the concentrated mixture was purified by column chromatography on silica gel eluting with petroleum ether/EtOAc (3:1 v/v) to give N-tert-butyl-2-(6-fluoro-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide (180 mg, 27%) as a white solid. LCMS: (M+H)+=595; 1H NMR (300 MHz, DMSO): δ 13.60 (s, 1H), 8.78 (s, 1H), 8.45-8.40 (m, 1H), 8.01 (s, 1H), 7.95 (s, 1H), 7.45-7.33 (m, 10H), 7.21-7.09 (m, 7H), 1.50 (s, 9H).

Aufarbeitung

  1. customthe mixture sonicated for 5 min
  2. customwhile bubbling nitrogen
  3. customAfter solvent removal
  4. customthe concentrated mixture was purified by column chromatography on silica gel eluting with petroleum ether/EtOAc (3:1 v/v)

Quellen und Nachweise

ORD-Eintrag
ord-d57040aa1a194223b5861539b724d9d9
Quelldatensatz
uspto-grants-2014_02
Patentnummer
US08658646B2

Verknüpfte Notizen

Wird geladen…